The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate

0477882 - ÚI 2018 US eng J - Článek v odborném periodiku
Soukup, T. - Doseděl, M. - Nekvindová, J. - Kuběna, A.A. - Tachecí, I. - Duintjer Tebbens, Jurjen - Vlček, J. - Bradna, P. - Barvík, I. - Pávek, P.
The plausible association of MTHFR and ADORA2A polymorphisms with nodules in rheumatoid arthritis patients treated with methotrexate.
Pharmacogenetics and Genomics. Roč. 27, č. 2 (2017), s. 43-50. ISSN 1744-6872. E-ISSN 1744-6880
Klíčová slova: modifying antirheumatic drugs * methylenetetrahydrofolate reductase * eular recommendations * a1298c polymorphisms * induced nodulosis * common mutation * 2013 update * risk-factor * adenosine * disease * adenosine and folate pathways * methotrexate * nodules * pharmacogenetics * rheumatoid arthritis
Kód oboru RIV: FR - Farmakologie a lékárnická chemie
Impakt faktor: 2.250, rok: 2017

Objective The treatment of rheumatoid arthritis (RA) patients with methotrexate (MTX) is linked to the development or progression of rheumatoid nodules. The aim of this study was to determine whether folate and adenosine pathways-related single nucleotide polymorphisms might be predictive of increased nodule formation in RA patients treated with oral MTX.
Trvalý link: http://hdl.handle.net/11104/0274101